香港股市 將在 5 小時 48 分鐘 開市

TEVA Jan 2025 13.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
4.8500+0.1000 (+2.11%)
市場開市。 截至 02:22PM EDT。
全螢幕
前收市價4.7500
開市4.8500
買盤4.2000
賣出價4.9500
拍板13.00
到期日2025-01-17
今日波幅4.8500 - 4.8500
合同範圍
成交量6
未平倉合約138
  • Reuters

    Teva sues Corcept over mifepristone 'monopoly' for rare disorder

    Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome. The lawsuit said Corcept and specialty pharmacy Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn.” Teva accused Corcept of "paying bribes and kickbacks" to physicians to keep them prescribing brand Korlym.

  • Zacks

    TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

    TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.

  • InvestorPlace

    Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

    Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden administration is attacking businesses across the board, such as its recent assault on the oil industry. Yet it risks killing off the drug discovery market with its actions by disincentivizing companies to find new treatments. For example, inventors of technology developed with federal funding retain